Proteins and Peptides
25 September 2013
Novo Nordisk – enrolment of Victoza® (liraglutide) cardiovascular outcomes trial completed on schedule with patient numbers exceeding target24 September 2013
Data Show Sanofi’s Lyxumia(R) Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled24 September 2013
BioMarin Doses First Patient in Phase 1/2 Trial With BMN 190 for the Treatment of Neuronal Ceroid Lipofuscinosis Type 2, a Form of Batten Disease23 September 2013
Versartis Presents Latest Positive Results From Its Pediatric Study of Long-Acting Growth Hormone Treatment at International Endocrinology Conference23 September 2013
New Data Evaluating Asfotase Alfa in Infants and Young Children with Hypophosphatasia (HPP) Presented at Paediatric Endocrinology Meeting20 September 2013
Novo Nordisk: NovoEight® (turoctocog alfa) receives positive opinion from the European regulatory authorities12 September 2013
Natural Human Interferon (Alpha-n3) is Active Against Both Wild-Type and Oseltamivir Resistant Avian-Origin Influenza A (H7N9) Virus11 September 2013
Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC11 September 2013
Phase 3 Data From The Medicines Company’s Oritavancin Solo Trials Featured at ICAAC Conference10 September 2013
ERYTECH Completes Enrollment in Its Phase III Study in Acute Lymphoblastic Leukemia10 September 2013
Camurus Receives Option-exercise Milestone for Octreotide FluidCrystal® Product CAM20299 September 2013
Biodel’s BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)9 September 2013
Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment3 September 2013
Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes2 September 2013
Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2]29 August 2013
Zealand announces peptide drug research and development collaboration agreement with Lilly20 August 2013
DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study20 August 2013
Handok-Genexine Long-Acting hGH Therapeutic “GX-H9” Receives Approval for Phase I Trial in Europe16 August 2013
Protalex Announces PRTX-100 Phase I Data Published in The Journal of Clinical Pharmacology15 August 2013
Altor BioScience Launches its Proprietary IL-15 Superagonist ALT-803 into Clinical Trials against CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports